BSE Grants Listing Approval to Nexome Capital Markets for 19,20,000 Preferential Equity Shares

Nexome Capital Markets Limited (formerly SMIFS Capital Markets Limited) has received listing approval from BSE Limited for 19,20,000 equity shares issued on a preferential basis through the conversion of warrants. The approval, communicated via BSE reference LOD/PREF/GB/FIP/195/2026-27 dated May 07, 2026, marks a significant step in the company's capital restructuring exercise under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Details of the Preferential Allotment

The newly listed shares carry a face value of Rs. 10/- each and were issued at a premium of Rs. 54/- per share. The allotment covers both Promoter and Non-Promoter categories, with the shares assigned distinctive numbers from 88,15,501 to 1,07,35,500. The table below summarises the key parameters of this preferential issue:

Parameter: Details Number of Shares: 19,20,000 equity shares Face Value: Rs. 10/- per share Issue Premium: Rs. 54/- per share Distinctive Numbers: 88,15,501 to 1,07,35,500 Allottee Category: Promoter and Non-Promoters Basis of Issue: Preferential allotment via warrant conversion BSE Approval Reference: LOD/PREF/GB/FIP/195/2026-27 Date of Approval: May 07, 2026

Regulatory Compliance Requirements

BSE has outlined several conditions that Nexome Capital Markets must fulfil before trading approval is granted for these shares. The exchange has directed the company to ensure compliance with Regulation 167 of SEBI (ICDR) Regulations and any subsequent SEBI directives. Additionally, in the event of a change exceeding two per cent of the total paid-up share capital, the company is required to file the shareholding pattern in XBRL mode as mandated under Regulation 31(1)(c) of SEBI LODR Regulations, 2015.

Conditions Precedent to Trading Approval

Trading approval for the aforementioned shares will be granted only upon the company submitting the following to BSE:

Listing approval from the National Stock Exchange of India Ltd. (if applicable)

Confirmation letters from NSDL/CDSL confirming the crediting of shares to respective beneficiary accounts or admission of capital to the depository system

Confirmation letters from NSDL/CDSL regarding lock-in of pre-preferential holding (if applicable)

Further, as per Schedule XIX of ICDR Regulations and SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, Nexome Capital Markets is required to apply for trading approval to the stock exchange(s) within seven working days from the date of grant of listing approval. Non-compliance with this requirement will attract fines as specified in the said SEBI circular.

Company Communication

The disclosure was filed by Sanjana Gupta, Company Secretary cum Compliance Officer of Nexome Capital Markets Limited, in accordance with Regulation 30 of SEBI (LODR) Regulations, 2015. The BSE listing approval letter was issued by Marian D'souza, Assistant Vice President, and Gaurav Bajare, Deputy Manager, on behalf of BSE Limited. The company is headquartered at Vaibhav, 4th Floor, 4 Lee Road, Kolkata, West Bengal – 700020.

Nexome Capital Markets Limited (formerly SMIFS Capital Markets Limited) has notified BSE Limited of a forthcoming Board of Directors meeting, scheduled for Monday, May 11, 2026. The intimation, dated May 05, 2026, was filed in compliance with Regulation 29(1)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The meeting is set to be held at the company's registered office — 'Vaibhav' (4F), 4, Lee Road, Kolkata – 700020 — at 04:00 P.M. The key details of the scheduled meeting are outlined below:

Parameter: Details Meeting Date: Monday, May 11, 2026 Meeting Time: 04:00 P.M. Venue: 'Vaibhav' (4F), 4, Lee Road, Kolkata – 700020 Intimation Filed On: May 05, 2026 Regulatory Reference: Regulation 29(1)(a), SEBI LODR Regulations, 2015

Agenda of the Meeting

The Board meeting has been convened to address the following items:

Consider and approve the Audited Financial Results for the quarter and year ended March 31, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Any other matter, if required, with the permission of the chair

Regulatory Compliance

The prior intimation has been submitted to BSE Limited in accordance with the applicable SEBI listing regulations. The filing was digitally signed by Sanjana Gupta, Company Secretary cum Compliance Officer of Nexome Capital Markets Limited, on May 05, 2026.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.